– The Company recently initiated a Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease – – Data disclosures anticipated from multiple clinical and pre-clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback